54 completed. 54 Phase 2, 6 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 54 | Completed 54 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 5 | Completed 5 |
Follow ATG: new trials by email Literature Review of ATG trials Research Report on ATG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TCD601 in de Novo Renal Transplant Recipients TCD601, belatacept, ATG - Renal Transplantation | Phase 2 | Completed | ITB-Med LLC | 76 | 2023-12-28 | 2026-05-05 |
| A Dose Escalation Study in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Completed | ITB-Med LLC | 13 | 2021-05-26 | 2025-02-27 |
| MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D) Anti-Human Thymocyte Immunoglobulin, Rabbit - Diabetes Mellitus, Type 1 | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 114 | 2020-11-24 | 2025-01-10 |
| Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation Belatacept, Tacrolimus, ATG - Lung Transplant Rejection, Antibody-mediated Rejection | Phase 2 | Completed | Washington University School of Medicine | 27 | 2019-12-17 | 2022-11-25 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Thymoglobulin, Fludarabine, Cyclophosphamide - Severe Aplastic Anemia, Aplastic Anemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 21 | 2016-09-01 | 2022-07-12 |
| MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs Thymoglobulin, Cyclophosphamide, Fludarabine - Epidermolysis Bullosa | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 17 | 2016-03-01 | 2024-09-19 |
| Regimen Optimization Study Thymoglobulin, Belatacept, mycophenolate mofetil(MMF) - Kidney Transplantation | Phase 2 | Completed | Bristol-Myers Squibb | 58 | 2015-12-31 | 2021-06-22 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil - Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Robert Lowsky | 18 | 2015-06-01 | 2021-06-24 |
| Minimal Islet Transplant at Diabetes Onset Human pancreatic islet, ATG, Pegylated G-CSF - Diabetes Mellitus, Type 1 | Phase 2 | Completed | Ospedale San Raffaele | 6 | 2015-04-01 | 2024-02-22 |
| Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging - Leukemia, Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2013-01-01 | 2020-05-05 |
| CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 27 | 2012-10-29 | 2024-07-23 |
| Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2012-10-25 | 2025-02-28 |
| Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG Fludarabine, Busulfan, NK cell infusion: - Leukemia, Chronic Myelogenous Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2012-01-01 | 2016-02-03 |
| Scleroderma Treatment With Autologous Transplant (STAT) Study Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide - Systemic Scleroderma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2011-09-15 | 2025-01-07 |
| NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases Preparative Regimen, NK Cells, Interleukin-2 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 25 | 2011-09-01 | 2020-05-13 |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders CIK cells, Cyclosporine, Mycophenolate Mofetil - Neural Tube Defects, Anemia | Phase 2 | Completed | Everett Meyer | 44 | 2011-03-01 | 2019-05-07 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 68 | 2010-07-15 | 2022-08-04 |
Showing 20 of 54. Sign in to see all of them.
Myelodysplastic Syndromes (12) · Leukemia (10) · Leukemia, Myeloid, Acute (10) · Hodgkin Disease (9) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Lymphoma (8) · Lymphoma, Non-Hodgkin (8) · Myeloproliferative Disorders (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Anemia, Aplastic (6) · Bone Marrow Failure Disorders (6) · Multiple Myeloma (5) · Burkitt Lymphoma (4) · Fanconi Anemia (4)
M.D. Anderson Cancer Center (13) · Masonic Cancer Center, University of Minnesota (11) · Fred Hutchinson Cancer Center (4) · National Cancer Institute (NCI) (3) · Stanford University (3) · Columbia University (2) · ITB-Med LLC (2) · Baylor College of Medicine (1) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · Everett Meyer (1) · Medical College of Wisconsin (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Northside Hospital, Inc. (1) · Ospedale San Raffaele (1)
United States (51) · Italy (3) · Austria (2) · Argentina (1) · Belgium (1) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1) · Slovenia (1) · United Kingdom (1)
Issa Khouri (2) · Jakub Tolar, MD, PhD (2) · Robert Lowsky (2) · Wen-Kai Weng (2) · Amanda Olson (1) · Amir Toor, MD (1) · Amy E DeZern, MD (1) · Angela Smith, MD (1) · Asad Bashey, MD, PhD (1) · Bernhard J. Hering, M.D. (1) · Brenda Cooper, MD (1) · Chitra M. Hosing, MD (1) · Claudio G. Brunstein, MD, PhD (1) · David A Margolis, MD (1)
PMID 18997171, PMID 19167681, PMID 20383216, PMID 21403127, PMID 21508125, PMID 21606164, PMID 21816832, PMID 22430088, PMID 23344397, PMID 24077845, PMID 24307695, PMID 26416896, PMID 30843184, PMID 30951840, PMID 31212080, PMID 32343796, PMID 32941647, PMID 34724566, PMID 37084383, PMID 37899481, PMID 37944074, PMID 39348419, PMID 39624016, PMID 40976248, PMID 41438972
P30CA015704 (3), P01HL036444 (2), 2019 (1), P01CA049605 (1), P01CA049639 (1), P30CA016672 (1), U10CA031946 (1), U10CA098543 (1), U10CA180821 (1)